AR051523A1 - Metodo para medir la resistencia o sensibilidad a docetaxel - Google Patents

Metodo para medir la resistencia o sensibilidad a docetaxel

Info

Publication number
AR051523A1
AR051523A1 ARP050105086A ARP050105086A AR051523A1 AR 051523 A1 AR051523 A1 AR 051523A1 AR P050105086 A ARP050105086 A AR P050105086A AR P050105086 A ARP050105086 A AR P050105086A AR 051523 A1 AR051523 A1 AR 051523A1
Authority
AR
Argentina
Prior art keywords
measuring
sensitivity
predict
concentrations
molecule
Prior art date
Application number
ARP050105086A
Other languages
English (en)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of AR051523A1 publication Critical patent/AR051523A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a métodos nuevos y utiles que pronostican o controlan una respuesta del paciente a una molécula de la familia de los taxoides midiendo el aumento o disminucion de los marcadores genéticos específicos comparados con las referencia. La presente también proporciona kits que pronostican o controlan la respuesta del paciente a una molécula de la familia de los taxoides midiendo las concentraciones de ácido nucleico o de proteínas de determinados marcadores genéticos y comparando sus concentraciones con referencias o marcadores de referencia.
ARP050105086A 2004-12-08 2005-12-06 Metodo para medir la resistencia o sensibilidad a docetaxel AR051523A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63429804P 2004-12-08 2004-12-08

Publications (1)

Publication Number Publication Date
AR051523A1 true AR051523A1 (es) 2007-01-17

Family

ID=36512512

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105086A AR051523A1 (es) 2004-12-08 2005-12-06 Metodo para medir la resistencia o sensibilidad a docetaxel

Country Status (16)

Country Link
US (2) US20090226894A1 (es)
EP (10) EP2395102A1 (es)
JP (5) JP5139811B2 (es)
KR (10) KR101357038B1 (es)
CN (10) CN102605066A (es)
AR (1) AR051523A1 (es)
AU (1) AU2005314335C1 (es)
BR (1) BRPI0518884A2 (es)
CA (1) CA2589918A1 (es)
HK (2) HK1111441A1 (es)
IL (9) IL183718A (es)
MX (1) MX2007006867A (es)
RU (2) RU2403574C2 (es)
SG (2) SG156625A1 (es)
TW (10) TW201237175A (es)
WO (1) WO2006062811A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606096D0 (en) * 2006-03-27 2006-05-03 Cbmm Sa Screening method
EP2102360A2 (en) * 2006-12-13 2009-09-23 Oncotherapy Science, Inc. Ttk as tumor marker and therapeutic target for lung cancer
EP2550976A3 (en) * 2007-03-14 2013-04-03 Bionsil S.r.l. Modulator compounds of the drug resistance in epithelial tumour cells
CA2706881A1 (en) * 2007-11-30 2009-06-11 Brian Z. Ring Tle3 as a marker for chemotherapy
EP2177630A1 (en) 2008-10-02 2010-04-21 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
ES2862340T3 (es) 2009-10-29 2021-10-07 Sanofi Mature Ip Nuevo uso antitumoral de cabazitaxel
WO2011124669A1 (en) 2010-04-08 2011-10-13 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
JP2012005479A (ja) * 2010-05-26 2012-01-12 Japanese Foundation For Cancer Research 抗癌剤のスクリーニング方法
CN103314295B (zh) * 2011-01-21 2016-03-16 巴斯利尔药物股份公司 Bubr1作为药物对呋咱并苯并咪唑响应的生物标记的用途
SG11201402143YA (en) * 2011-11-21 2014-06-27 Taivex Therapeutics Corp Biomarkers for cancers responsive to modulators of hec1 activity
EP2786140A4 (en) * 2011-11-28 2015-10-28 Nat Res Council Canada PACLITAXEL REACTION MARKERS FOR CANCER
CN102621325B (zh) * 2012-04-06 2014-11-12 上海蓝怡科技有限公司 用于检测血液中多西他赛浓度的试剂盒
CN105803053B (zh) * 2014-12-31 2021-03-16 上海吉凯基因科技有限公司 人rbm17基因的用途及其相关药物
CN105925611A (zh) * 2016-04-23 2016-09-07 同济大学苏州研究院 靶向hsp70基因rna干扰重组慢病毒载体及其构建方法
CN107447028A (zh) * 2017-09-13 2017-12-08 赵小刚 检测rb1基因i680t位点突变的试剂盒
CN108931633B (zh) * 2018-05-22 2021-08-27 郑州大学第一附属医院 胆囊癌诊断和预后判断标志物pim1
CN111944905B (zh) * 2020-08-20 2023-06-02 武汉凯德维斯医学检验实验室有限公司 人类基因组合及其在制备评估宫颈癌新辅助化疗药物敏感性试剂盒中的应用
KR102596893B1 (ko) 2022-03-04 2023-11-01 우순 표적지 이송장치
KR102605155B1 (ko) 2022-03-04 2023-11-23 우순 다기능 표적 이송장치

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7807532A (nl) 1978-07-13 1980-01-15 Akzo Nv Metaal-immunotest.
NL8000173A (nl) 1980-01-11 1981-08-03 Akzo Nv Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
JPS61231031A (ja) * 1985-04-08 1986-10-15 Agency Of Ind Science & Technol 二硫化炭素重合体の製造方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0280559B1 (en) 1987-02-27 1993-10-20 EASTMAN KODAK COMPANY (a New Jersey corporation) Agglutination immunoassay and kit for determination of a multivalent immune species using a buffered salt wash solution
JPH0664061B2 (ja) 1987-02-27 1994-08-22 イーストマン コダック カンパニー 免疫反応性試薬、その製造法及び免疫反応性種を測定するためのその用途
US4857453A (en) * 1987-04-07 1989-08-15 Syntex (U.S.A.) Inc. Immunoassay device
ES2184734T3 (es) 1987-04-27 2003-04-16 Inverness Medical Switzerland Dispositivo de prueba analitica para realizar ensayos de union especifica.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5834298A (en) * 1995-08-01 1998-11-10 Sloan-Kettering Institute For Cancer Research Gene encoding the human homolog of MAD2
EP0983359A1 (en) * 1997-06-11 2000-03-08 Chiron Corporation DETECTION OF LOSS OF THE WILD-TYPE $i(hu)BUB1 GENE
US6410312B1 (en) * 1997-12-19 2002-06-25 Chiron Corporation huBUB3 gene involved in human cancers
AU750564B2 (en) * 1997-11-27 2002-07-25 Chugai Seiyaku Kabushiki Kaisha Examination method, examination reagent and remedy for diseases caused by variation in LKB1 gene
ATE238556T1 (de) * 1998-02-18 2003-05-15 Theryte Ltd Krebsbehandlung
WO2000017648A1 (en) * 1998-09-24 2000-03-30 Promega Corporation Apoptosis marker antibodies and methods of use
AU2055300A (en) * 1998-12-18 2000-07-03 Scios Inc. Methods for detection and use of differentially expressed genes in disease states
US20020120004A1 (en) * 2000-02-17 2002-08-29 Roth Frederick P. Methods and compositions for the identification, assessment, prevention and therapy of human cancers
WO2001061048A2 (en) * 2000-02-17 2001-08-23 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification, assessment, prevention and therapy of human cancers
CA2438092C (en) * 2001-02-21 2011-08-09 Chiron Corporation Ttk in diagnosis and as a therapeutic target in cancer
US6783597B2 (en) * 2001-03-13 2004-08-31 3M Innovative Properties Company Filament recoating apparatus and method
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
DE10139283A1 (de) * 2001-08-09 2003-03-13 Epigenomics Ag Verfahren und Nukleinsäuren zur Analyse von Colon-Krebs
US20030235581A1 (en) * 2002-06-20 2003-12-25 George Pieczenik Ligands for Reproductive Science
US20120045390A1 (en) * 2002-09-11 2012-02-23 Genentech, Inc. Composition and Methods for the Diagnosis and Treatment of Tumor
US20040214203A1 (en) * 2002-12-12 2004-10-28 Oncotech, Inc. Genes related to sensitivity and resistance to chemotherapeutic drug treatment
DE10260264A1 (de) * 2002-12-20 2004-07-01 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verfahren und Zelllinie zur Identifizierung proliferationshemmender, anti-inflammatorischer oder proliferationsfördender Wirkstoffe
EP1661991A4 (en) * 2003-08-24 2007-10-10 Univ Nihon WITH HEPATOCELLULAR CARCINOMA ASSOCIATED GEN
US20050136177A1 (en) * 2003-08-25 2005-06-23 Anthony Hesse Method for coloring landscaping materials using foamable dry colorant
US7871769B2 (en) * 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
JP2006014722A (ja) * 2004-06-02 2006-01-19 Keio Gijuku 遺伝子マーカー及びその利用
GB0426393D0 (en) * 2004-12-01 2005-01-05 Cancer Rec Tech Ltd Materials and methods relating to modulators of spindle checkpoint kinases
US7957910B2 (en) * 2005-01-31 2011-06-07 Sysmex Corporation Method for predicting effectiveness of chemotherapy
EP2177630A1 (en) * 2008-10-02 2010-04-21 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family

Also Published As

Publication number Publication date
CN102618641B (zh) 2014-08-13
CN102634574B (zh) 2014-11-12
CN102618642B (zh) 2014-12-31
KR101357037B1 (ko) 2014-02-03
TW201241176A (en) 2012-10-16
EP2395104A1 (en) 2011-12-14
KR101357035B1 (ko) 2014-02-03
CN101974619B (zh) 2012-11-21
IL225468A0 (en) 2013-06-27
IL205702A0 (en) 2011-07-31
AU2005314335B2 (en) 2012-02-02
TW201237179A (en) 2012-09-16
CN102747142A (zh) 2012-10-24
KR20130105760A (ko) 2013-09-25
KR20130105761A (ko) 2013-09-25
AU2005314335A1 (en) 2006-06-15
RU2007125722A (ru) 2009-01-20
CN101974619A (zh) 2011-02-16
IL221772A0 (en) 2012-10-31
EP2395108A1 (en) 2011-12-14
KR20130105758A (ko) 2013-09-25
TW201237178A (en) 2012-09-16
WO2006062811A3 (en) 2006-09-14
KR20130113526A (ko) 2013-10-15
US20090226894A1 (en) 2009-09-10
CN102634574A (zh) 2012-08-15
EP2395106A1 (en) 2011-12-14
KR20130113527A (ko) 2013-10-15
HK1153786A1 (en) 2012-04-05
JP2012100666A (ja) 2012-05-31
JP2008522615A (ja) 2008-07-03
JP2012100665A (ja) 2012-05-31
KR101357033B1 (ko) 2014-02-03
KR101357039B1 (ko) 2014-02-03
IL210298A0 (en) 2011-03-31
KR20130099246A (ko) 2013-09-05
CN102747140A (zh) 2012-10-24
US20130252837A1 (en) 2013-09-26
EP1831398B1 (en) 2014-10-29
EP2395103A1 (en) 2011-12-14
EP2395110A1 (en) 2011-12-14
CN101072883A (zh) 2007-11-14
KR20130105759A (ko) 2013-09-25
IL210299A0 (en) 2011-03-31
KR101357032B1 (ko) 2014-02-03
KR101347107B1 (ko) 2014-01-02
JP5531000B2 (ja) 2014-06-25
IL210299A (en) 2012-12-31
CN102605066A (zh) 2012-07-25
KR101357038B1 (ko) 2014-02-03
MX2007006867A (es) 2007-08-06
IL205636A (en) 2012-08-30
JP2012120532A (ja) 2012-06-28
CN102618642A (zh) 2012-08-01
RU2010122759A (ru) 2011-12-10
IL225469A0 (en) 2013-06-27
TW201241177A (en) 2012-10-16
CN102605067A (zh) 2012-07-25
KR101357040B1 (ko) 2014-02-03
TW201241178A (en) 2012-10-16
TW201237175A (en) 2012-09-16
KR20130105762A (ko) 2013-09-25
EP2395102A1 (en) 2011-12-14
IL205635A (en) 2013-02-28
SG194337A1 (en) 2013-11-29
RU2403574C2 (ru) 2010-11-10
CN102747141A (zh) 2012-10-24
IL183718A (en) 2013-04-30
EP2395107A1 (en) 2011-12-14
EP1831398A2 (en) 2007-09-12
EP2395105A1 (en) 2011-12-14
CN102618641A (zh) 2012-08-01
TW201237174A (en) 2012-09-16
CN101072883B (zh) 2012-05-23
TW201237177A (en) 2012-09-16
KR20130004381A (ko) 2013-01-09
IL183718A0 (en) 2007-09-20
BRPI0518884A2 (pt) 2008-12-30
KR101323574B1 (ko) 2013-10-30
JP5139811B2 (ja) 2013-02-06
KR20070085986A (ko) 2007-08-27
JP5531002B2 (ja) 2014-06-25
SG156625A1 (en) 2009-11-26
AU2005314335C1 (en) 2012-08-16
HK1111441A1 (en) 2008-08-08
JP2012115267A (ja) 2012-06-21
TW201237176A (en) 2012-09-16
KR101347106B1 (ko) 2014-01-02
EP2395109A1 (en) 2011-12-14
TW200636076A (en) 2006-10-16
CA2589918A1 (en) 2006-06-15
IL210298A (en) 2012-12-31
JP5530999B2 (ja) 2014-06-25
WO2006062811A2 (en) 2006-06-15
JP5531001B2 (ja) 2014-06-25
IL221772A (en) 2014-06-30

Similar Documents

Publication Publication Date Title
AR051523A1 (es) Metodo para medir la resistencia o sensibilidad a docetaxel
CY1111612T1 (el) Μεθοδος για προβλεψη της αποκρισης σε μια θεραπευτικη αγωγη με εναν αναστολεαδιmερισmου του her
AR064509A1 (es) Promotores inducibles por el gen peroxidasa del nematodo y metodos de uso
CY1116279T1 (el) Η χρηση των ανθρωπινων κυτταρων προελευσης μυελογενους λευχαιμιας για την εκφραση αντισωματων
BR112013033488A2 (pt) marcadores biológicos de micro-rna indicativo da doença de alzheimer
ECSP088228A (es) Secuencias de nucleótidos que codifican proteínas insecticidas
BRPI0702851A (pt) método e aparelho pra prover informação de congestionamento e tempo de viagem aos usuários
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
ES2720999T3 (es) Método y sistema para seleccionar un fármaco sobre la base de la información del daño de proteína individual para prevenir los efectos secundarios de un fármaco
PE20211214A1 (es) Variantes de pertuzumab y su evaluacion
BR112018074853A2 (pt) métodos para detectar a presença de pelo menos um genogrupo de norovírus em uma amostra de fezes e para selecionar um paciente que sofre de gastroenterite aguda, e, kit
AR063493A1 (es) Nuevos anticuerpos anti notch 3 y su uso para la deteccion y el diagnostico de enfermedades
JP2014160088A5 (es)
DE602006013333D1 (de) Kit und verfahren zum nachweis von urothelkarzinom
BR112018069316A2 (pt) métodos para detectar presença de pelo menos uma espécie de bordetella patogênica e selecionar um paciente que exibe sintomas semelhantes à coqueluche, e, kit para detectar presença de pelo menos uma espécie de bordetella patogênica.
ATE493655T1 (de) Neuer potentiometrischer cholesterinsensor zur quantitativen abschätzung des gesamtcholesterins in menschlichem blutserum
BRPI0415277A (pt) célula, vetor, método para produzir proteìna gama-carboxilada, proteìna gama-carboxilada isolada, uso da mesma, método para produzir uma composição farmacêutica, composição farmacêutica, método para produzir fator x de humano gama-carboxilado, uso de fator x isolado, método para produzir protrombina de humano gama-carboxilada, uso de protrombina isolada, e, método para promover coagulação aumentada ou diminuìda em um indivìduo
DE602006015702D1 (de) Unterscheidung zwischen baktiereller meningitis und viraler meningitis
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
AR058510A1 (es) Procedimiento de diagnostico de enfermedades hepaticas y de muestreo de moleculas para el tratamiento de estas enfermedades
AR070933A1 (es) Ensayo basado en fluorescencia para detectar compuestos que modulan el modo inverso del intercambiador de sodio /calcio (ncx)
ES2516717T3 (es) Proteína activadora de GM2 en orina como marcador de fallo renal agudo o de riesgo de desarrollar fallo renal agudo
AR059326A1 (es) Resistencia a la mastitis
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
BRPI0418022A (pt) biomarcadores para sensibilidade de doenças proliferativas a inibidores de mtor

Legal Events

Date Code Title Description
FB Suspension of granting procedure